Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed in Advanced Neuroendocrine Tumors
NCT00424723Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2005
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pemetrexed in neuroendocrine tumors (NETs), sponsored by Dana-Farber Cancer Institute. Started Dec 2005; status: completed.
02
Drugs
pemetrexed
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT00424723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00424723.